NVIDIA
NVDA
Tesla
TSLA
Disney
DIS
Apple
AAPL
Netflix
NFLX
US Stock MarketDetailed Quotes
CABA Cabaletta Bio
- 1.805
- -0.005-0.28%
Close Feb 28 16:00 ET
- 1.910
- +0.105+5.82%
Post 18:15 ET
88.22MMarket Cap-0.84P/E (TTM)
1.920High1.710Low1.29MVolume1.820Open1.810Pre Close2.37MTurnover3.11%Turnover RatioLossP/E (Static)48.88MShares23.98052wk High0.51P/B75.03MFloat Cap1.71052wk Low--Dividend TTM41.57MShs Float26.350Historical High--Div YieldTTM11.60%Amplitude0.590Historical Low1.832Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Cabaletta Bio Stock Forum
“Title: Clinical and Translational Studies of Rese-cel (an anti-CD19 CAR T Therapy) in Myositis, SLE, and Systemic Sclerosis: RESET Phase I/II Trials
Date and Time: Saturday, February 22, 2025, 10:15 a.m. – 10:30 a.m. CET
*Additional information can be accessed on the website of each scientific meeting. Presentation materials will be made available on the Posters & Publications section of the Company's website following each event.
About rese-cel (formerly referred to ...
The latest clinical data from Cabaletta Bio's rese-cel program represents a significant milestone in autoimmune disease treatment. The achievement of DORIS remission in 3 out of 4 SLE patients, complete renal response in lupus nephritis, and sustained improvement in dermatomyositis - all while discontinuing immunosuppressants - suggests a potentially transformative therapeutic approach.
The confirmed deep B cell depletion, both in circulation and ...
Breakthrough Clinical Results: Rese-cel Treatment Achieves Remission in Lupus Patients, Shows Promise Across Autoimmune Disorders
Revolutionary Autoimmune Treatment Success: Patients Achieve Complete Remission, Stop All Medications
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses Across Multiple Indications With Rese-Cel at February Scientific Meetings
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Tuesday, 18th February at 7:00 am
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosu...
No comment yet